Although TNFα is not directly involved in JAK/STAT signaling, there is evidence of indirect contributions of this cytokine to the pathway (Hu et al., 2021) that may explain why SAVI patients tend to benefit from JAK inhibitor treatment despite sustained IFN scores. This evidence concerns the gene SOAT1 and STING-associated vasculopathy with onset in infancy.